Psychedelic drug development is moving into a more consequential phase. Compounds such as MDMA, psilocybin, LSD, and other psychoactive agents continue to be explored for serious mental health conditions, including post-traumatic stress disorder, treatment-resistant depression, major depressive disorder, and substance...
Expertise: Neuroscience 46 results
Neuroscience
3 Shifts Reshaping Alzheimer’s Trial Execution
Learn how evolving FDA programs, modern trial designs, and patient-centered practices are reshaping rare disease development.
Neuroscience
ASCP
Neuroscience
SIRS Annual Congress
Consulting
ISCDD International Meeting
Neuroscience
AD/PD 2026
Parkinson’s disease is one of the fastest-growing neurological disorders worldwide, supported by a robust and diverse clinical research pipeline. As understanding of disease biology continues to advance, there is growing recognition that traditional trial designs and endpoints may not fully...
Parkinson’s disease (PD) affects an estimated 10 million people worldwide, including more than 1.1 million in the United States. With prevalence rising as the population ages, experts warn of a growing public health crisis and an economic burden that exceeds...
Neuroscience
Raising the Bar in Global MDD Research
Neuroscience